[A trend of insulin sensitizer which is under development].
Kadowaki
T
T
Department of Metabolic Diseases, Graduate School of Medicine, University of Tokyo.
D000818:Animals; D001565:Benzoates; D001713:Biphenyl Compounds; D002986:Clinical Trials as Topic; D015195:Drug Design; D006801:Humans; D007004:Hypoglycemic Agents; D007333:Insulin Resistance; D000077205:Pioglitazone; D018160:Receptors, Cytoplasmic and Nuclear / Q000819:agonists / Q000037:antagonists & inhibitors; D018168:Receptors, Retinoic Acid / Q000037:antagonists & inhibitors; D047488:Retinoid X Receptors; D013844:Thiazoles / Q000009:adverse effects / Q000627:therapeutic use; D045162:Thiazolidinediones; D014157:Transcription Factors / Q000819:agonists / Q000037:antagonists & inhibitors
D001565:Benzoates; D001713:Biphenyl Compounds; D007004:Hypoglycemic Agents; D018160:Receptors, Cytoplasmic and Nuclear; D018168:Receptors, Retinoic Acid; D047488:Retinoid X Receptors; D013844:Thiazoles; D045162:Thiazolidinediones; D014157:Transcription Factors; C438269:diazepinylbenzoic acid; D000077205:Pioglitazone